Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1320
Shown on this page
12
Current sort
Recently updated
Campus scope
Cleveland Clinic, Cleveland, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cleveland Clinic, Cleveland, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 445–456 of 1,320 matching trials with a site at Cleveland Clinic, Cleveland, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

NCT06412510
Site status not listed — check the official record
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma
Interventions
Prehabilitation
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting Phase 2 Interventional

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

NCT04996875
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
Interventions
bezuclastinib
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

NCT06687603
Status at this site: Recruiting
View directory record Official record
Conditions
Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
Interventions
EsoCheck, EsoGuard
Device · Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
50 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Active, not recruiting Not applicable Interventional

Abbreviated MBCT for Depression in Older Black or African American Breast Cancer Survivors

NCT06336538
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Mild Depression, Moderate Depression
Interventions
MBCT
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

NCT06150183
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Malignant Solid Tumor
Interventions
BNT314
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Grand Rapids, Michigan • Huntersville, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions
BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting Phase 3 Interventional

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

NCT04462770
Status at this site: Recruiting
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Not yet recruiting Not applicable Interventional

Upper Extremity Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

NCT07810790
Site status not listed — check the official record
View directory record Official record
Conditions
Functional Recovery, Upper Extremity Vascularized Composite Allotransplantation
Interventions
Upper Extremity Vascularized Composite Allotransplantation (VCA)
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2037
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986
Site status not listed — check the official record
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
46
States / cities
Dothan, Alabama • Lancaster, California • Orange, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting Phase 3 Interventional

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

NCT04575935
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Serous Neoplasm, Fallopian Tube Transitional Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Chemotherapy, Laparotomy, Minimally Invasive Surgery, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
13
States / cities
Miami, Florida • Weston, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biospecimen Repository for Cardiac Arrhythmias at the Cleveland Clinic

NCT00921986
Status at this site: Recruiting
View directory record Official record
Conditions
Arrhythmias, Cardiac
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2035
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 9:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT04115631
Site status not listed — check the official record
View directory record Official record
Conditions
Liver Lymphoma, Mantle Cell Lymphoma
Interventions
Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Drug · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
504
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 358 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 9:06 PM EDT

About this Cleveland Clinic institution page

What this page lists
ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.